{"filing":{"accession_number":"0001493152-26-048114","cik":"0001799011","ticker":"LUCD","company_name":"Lucid Diagnostics Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-21","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226048114/form8-k.htm"},"events":[{"id":37308,"run_id":34392,"accession_number":"0001493152-26-048114","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses an unregistered sale of 15,000 shares of Series C Convertible Preferred Stock to accredited investors for $15.0 million aggregate proceeds on October 21, 2026, under Item 3.02. The Series C Preferred Stock is convertible into common stock at an initial conversion price of $0.3519 per share, with significant dilutive features including 20% annual dividends payable in common stock, a 300% liquidation preference, and director designation rights. This is a classic private placement of convertible securities that will substantially dilute existing common shareholders upon conversion.","company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":41973,"accession_number":"0001493152-26-048114","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of 15,000 shares of Series C Convertible Preferred Stock to accredited investors for $15.0 million aggregate proceeds on October 21, 2026, under Item 3.02. The Series C Preferred Stock is convertible into common stock at an initial conversion price of $0.3519 per share, with significant dilutive features including 20% annual dividends payable in common stock, a 300% liquidation preference, and director designation rights. This is a classic private placement of convertible securities that will substantially dilute existing common shareholders upon conversion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:35:40.602380+00:00","company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","filing_date":"2026-10-22"}]}